Antimicrobials
Ceftazidime

Ceftazidime

High
N/A

Dosing

General Information

HEALTH CANADA APPROVED

  • Treatment of infections of the lower respiratory or urinary tracts, skin structure and bone; also peritonitis, septicemia and meningitis when caused by susceptible organisms

Vitamin K antagonists (eg, warfarin): may enhance the anticoagulant effect of Vitamin K antagonists. Monitor therapy.

LOCAL REACTIONS

  • Thrombophlebitis and pain on injection

HYPERSENSITIVITY

  • Anaphylaxis, including bronchospasm and hypotension (rare)
  • Urticaria, pruritus, fever, eosinophilia, hemolytic anemia

GASTROINTESTINAL

  • Diarrhea, nausea, vomiting, abdominal pain
  • Pseudomembranous colitis (rare)

HEPATIC

  • Transient increases in serum bilirubin, alkaline phosphatase, AST and ALT

MISCELLANEOUS

  • Seizures (associated with high doses in uremic patients)

Can be given IM

Subcutaneous use: no information available at this time

Antimicrobial class: 3rd generation Cephalosporin Antibiotic

Pregnancy category: B

Average serum half life: 2 hours

Urine penetration: Therapeutic

Lung penetration: Therapeutic

CSF penetration: Therapeutic

Biliary penetration: Moderate

pH: 5 to 8